Abstract
Abstract only
- Title
- Cost-effectiveness of maintenance therapy in advanced ovarian cancer: Paclitaxel, bevacizumab, niraparib, rucaparib, olaparib, and pembrolizumab
- Creators
- Juliet Elizabeth Wolford - University of California, IrvineJiaru Bai - Binghamton UniversityLindsey E. Minion - University of California, IrvineRobin Keller - University of California, IrvineRamez Nassef Eskander - UCSD, Moores Cancer Center, La Jolla, CA;John K. Chan - Palo Alto Medical FoundationBradley J. Monk - Dignity HealthKrishnansu Sujata Tewari - University of California, Irvine
- Publication Details
- Journal of clinical oncology, Vol.36(15_suppl), pp.5508-5508
- Identifiers
- 991005969013202656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article